Anti-tumour necrosis factor agents and lipid profile: A class effect?

Annals of the Rheumatic Diseases

Volumn 67, Issue 6, 2008, Pages 895-896

  Garcês Da Gama, Sandra Pinheiro ^a   Parreira Santos, M J ^a   Vinagre, F M R ^a   Roque, R M ^a   Da Silva, J A C ^a  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ETANERCEPT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN; STEROID; TRIACYLGLYCEROL;

ANKYLOSING SPONDYLITIS; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DRUG EFFECT; HUMAN; LETTER; LIPID BLOOD LEVEL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPID METABOLISM; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45149086929     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.078287     Document Type: Letter

References (8)

1. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, et al. Influence of anti tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
2. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.
3. Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143-8.
4. Spanakis E, Sidiropoulos P, Papadakis J, Emmanuel G, George K, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheum 2006;33:2440-6.
5. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414-19.
6. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7.
7. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long- term infliximab therapy. Scand J Rheumatol 2006;35:107-11.
8. Scheryer SA, Vick CM, LeBouef RC. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J Biol Chem 2002;277:12364-8.